Real World Value: Advancing Payer Understanding of RWE in Rare Disease
Drug developers and regulators are expanding the use of real world evidence to design, test and review rare disease treatments. But market access challenges persist as payers in the U.S. and Europe continue to express doubts. A new survey sheds light on the perception gap. A striking life sciences trend ...